中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.027 seconds)

    TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING
    2.
    发明申请
    TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING 审中-公开
    三聚体化合物及其作为细胞因子信号抑制剂的模拟物

    公开(公告)号：WO02068421A3

    公开(公告)日：2003-07-31

    申请号：PCT/US0143048

    申请日：2001-11-09

    Applicant: CELL THERAPEUTICS INC ,  GONG BAOQING ,  KLEIN J PETER ,  COON MICHAEL

    Inventor： GONG BAOQING ,  KLEIN J PETER ,  COON MICHAEL

    IPC: A61K31/519 ,  A61K31/522 ,  A61K31/675 ,  A61P1/04 ,  A61P3/10 ,  A61P11/06 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D487/14 ,  C07D513/14 ,  C07D437/04 ,  A61K31/52 ,  C07D487/04

    CPC classification number: C07D487/14 ,  A61K31/522 ,  A61K31/675 ,  C07D513/14

    Abstract: Novel tricyclic compounds having the formula (II) or (I), wherein: R1 is optionally substituted and selected from a member of the group consisting of hydrogen, methyl, C1-20alkyl, C1-20alkenyl, C1-20alkynyl, C1-20hydroxyalkyl, C1-20cyanoalkyl, C1-20alkoxyl, and C1-20alkoxyalkyl R2 and R3 join to form an optionally substituted heterocycle, each R2 and R3 being independantly selected from a member of the group consisting of hydrogen, halo, thio, oxo, C1-20alkyl, C1-20hydroxyalkyl, C1-20thioalkyl, C1-20alkylthio, C1-20alkylamino, C1-20alkylaminoalkyl, C1-20aminoalkyl, C1-20aminoalkyloxyalkenyl, C1-20aminoalkyloxyalkynyl, C1-20diaminoalkyl, C1-20triaminoalkyl, C1-20tetraaminoalkyl, C1-20aminotrialkoxyamino, C1-20alkylamido, C1-20alkylamidoalkyl, C1-20amidoalkyl, C1-20acetamidoalkyl, C1-20alkenyl, C1-20alkynyl, C1-20alkoxyl, C1-20alkoxyalkyl, and C1-20dialkoxyalkyl, are found to be used for the treatment or prevention of symptoms of manifestations associated with diseases or disorders affected by cytosine and intracellular signaling.

    Abstract translation: 具有式（II）或（I）的新型三环化合物，其中：R 1任选被取代并选自氢，甲基，C 1-20烷基，C 1-20烯基，C 1-20炔基，C 1-20羟烷基， C 1-20烷酰基，C 1-20烷氧基烷基和C 1-20烷氧基烷基R 2和R 3连接形成任选取代的杂环，每个R 2和R 3独立地选自氢，卤素，硫代，氧代，C 1-20烷基， C 1-20烷氧基烷基，C 1-20二氨基烷基，C 1-20二氨基烷基，C 1-20二氨基烷基，C 2-20氨基三烷氧基氨基，C 1 -C 20烷基氨基烷基， 20个烷基酰氨基，C 1-20烷基酰氨基烷基，C 1-20氨基烷基，C 1-20乙酰胺基烷基，C 1-20烯基，C 1-20炔基，C 1-20烷氧基，C 1-20烷氧基烷基和C 1-20二烷氧基烷基被用于治疗或预防相关表现的症状 与疾病或病症affec 由胞嘧啶和细胞内信号传导。

    8.
    发明专利
    未知

    公开(公告)号：BR0014652A

    公开(公告)日：2003-06-10

    申请号：BR0014652

    申请日：2000-10-12

    Applicant: CELL THERAPEUTICS INC

    Inventor： KUMAR ANIL M ,  KLEIN J PETER ,  BHATT RAMA ,  VANTER EDWARD

    IPC: A61K31/337 ,  A61K31/427 ,  A61K31/4745 ,  A61K47/42 ,  A61K47/48 ,  A61P35/00

    Abstract: The present invention relates to conjugates comprising a polyglutamic acid polymer covalently bonded to a camptothecin molecule selected from the group consisting of 20(S)(+)-camptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, 7-ethyl-10-hydroxycamptothecin, 9-dimethyl-aminomethyl-10-hydroxycamptothecin and 7-methylpiperizinomethyl-10,11-ethylenedioxy-camptothecin. The present invention also relates to such compounds as medicaments, in particular for the treatment of cancer.

    Second messenger cell signaling onhibitors
    10.
    发明专利
    Second messenger cell signaling onhibitors 未知

    公开(公告)号：ZA942317B

    公开(公告)日：1995-02-10

    申请号：ZA942317

    申请日：1994-03-31

    Applicant: CELL THERAPEUTICS INC

    Inventor： MICHNICK JOHN ,  UNDERSINER GAIL E ,  KLEIN J PETER ,  RICE GLENN C ,  SUNKARA PRASAD S

    IPC: A61K31/404 ,  A61K31/45 ,  A61K31/47 ,  A61K31/513 ,  A61K31/519 ,  A61K31/522 ,  C07C215/08 ,  C07C215/56 ,  C07C217/62 ,  C07C229/22 ,  C07C233/36 ,  C07C233/78 ,  C07C233/91 ,  C07D207/40 ,  C07D207/404 ,  C07D209/48 ,  C07D211/76 ,  C07D211/88 ,  C07D217/24 ,  C07D239/54 ,  C07D239/90 ,  C07D239/96 ,  C07D295/13 ,  C07D473/10 ,  A61K ,  C07C ,  C07D

    Abstract: Therapeutic compounds have the formula:(X)j-(core moiety),j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH2)m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH2)n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R1 and R2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or -(CH2)wR5, w being an integer from two to fourteen and R5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxyl. Or jointly, R1 and R2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R3 is a hydrogen or C1-3. Or, therapeutic compounds may also have the formula: ed chain alkyl or alkenyl of up to eight carbon atoms in length, -(CH2)wR5, w being an integer from two to fourteen and R5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxyl, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH2)s or (CH2)t may be substituted by a keto or hydroxyl group.

Patent Agency Ranking